US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

ホーム
投資
ETF
イギリス
LSE
Arqiva Financing Plc (20BZ) 銘柄情報

Arqiva Financing Plc (20BZ)

113.954

0.00

(0.00%)

終了 7月4日 12:30AM

Arqiva Financing Plc (20BZ) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

113.954

( - )

買値

113.954

売値

113.954

出来高

-

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

前日終値

113.954

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

£ 0

発行済株式数

-

配当利回り

PER

-

1 株当たり利益 (EPS)

-

歳入

-

純利益

4k

Arqiva Financing Plc operates as a debt issuing vehicle. The company was incorporated in 2012 and is based in Winchester, United Kingdom. Arqiva Financing Plc operates as a subsidiary of Arqiva Group Intermediate Limited. Arqiva Financing Plc operates as a debt issuing vehicle. The company was incorporated in 2012 and is based in Winchester, United Kingdom. Arqiva Financing Plc operates as a subsidiary of Arqiva Group Intermediate Limited.

セクター

-

業界

-

本社

Winchester, United Kingdom

設立

2026

Arqiva Financing Plc is listed in the sector of the ロンドン証券取引所 with ticker 20BZ. The last closing price for Arqiva Financing was £113.95. Over the last year, Arqiva Financing shares have traded in a share price range of £ 0.00 to £ 0.00.

Arqiva Financing currently has shares in issue.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
LIMENeutron Holdings Inc	US$ 25.10 (1,430.49%)	1.12M
CLROClearOne Inc	US$ 6.4788 (101.20%)	88.54M
CWDCaliberCos Inc	US$ 1.21 (87.51%)	338.03M
MIDDVMiddleby Corporation	US$ 139.52 (72.23%)	1.54k
DSYBig Tree Cloud Holdings Limited	US$ 4.44 (54.17%)	22.72M
TCToken Cat Ltd	US$ 2.9699 (-38.13%)	1.66M
LHAILinkhome Holdings Inc	US$ 1.7252 (-37.04%)	20.13M
ELTXElicio Therapeutics Inc	US$ 3.26 (-36.58%)	4.35M
NCRANocera Inc	US$ 0.0647 (-35.69%)	10.63M
JLHLJulong Holding Limited	US$ 7.33 (-33.90%)	150.01k
LIMNLiminatus Pharma Inc	US$ 0.1365 (18.90%)	525.18M
CWDCaliberCos Inc	US$ 1.21 (87.51%)	338.03M
INLFINLIF Limited	US$ 0.022 (-32.93%)	219.73M
SURGSurgePays Inc	US$ 0.578 (39.31%)	178.02M
NVDANVIDIA Corporation	US$ 194.83 (-1.39%)	143.34M

williamssc

williamssc 1分前

Slide16 “Overall Conclusions: The survival benefit associated with DCVax-L treatment reflects a true treatment affect and was underestimated in the original analysis”

NASDAQ2020

NASDAQ2020 3分前

i will wait for Monday to grab some more ??

GoodGuyBill

GoodGuyBill 3分前

Brazen22, you’re trying to reduce three years of regulatory progress to one sentence: “You don’t have an approved MAA.”

Of course we don’t — yet. Approval is the destination. We have a validated MAA. What matters is whether NWBO has completed the steps that regulators require before a

NASDAQ2020

NASDAQ2020 3分前

THATS WHEN i ACCUMULATE. At The hammerbottom.

nowwhat2

nowwhat2 3分前

https://investorshub.advfn.com/uimage/uploads/2026/7/3/vwgethg_july_3_2y_plunge_sell.jpg

rizona

Slides! JAMA study UNDERESTIMATED survival benefit

https://nwbio.com/wp-content/uploads/NWBT-BNOS-slides-7-3-26MB-LP-final.pdf

rosemountbomber

rosemountbomber 6分前

I agree with your thinking and also what needs to be considered is after decimating the board, just a desire to be acquired doesn’t automatically make that happen. Some other party has to be interested in acquiring Amarin. What happens then if no one steps up?

chereb19

chereb19 7分前

This is another post built on false equivalence. Sharing Y-90 doesn't make two products the same any more than sharing aspirin makes every painkiller identical.

You keep calling them competitors while ignoring they're fundamentally different technologies. One is a hydrogel platform, t

NASDAQ2020

NASDAQ2020 8分前

Im glad I held my shares past $0.15

Idunno

And don’t forget your buddy, AF. … .. .

Doc logic

Doc logic 8分前

HappyLibrarian,

You are mistakenly overstating my claim which is a common problem so no harm no foul. Manufacturing transition preparedness is what I am suggesting must be in place. Artisan will be utilized to start as NWBO has consistently stated and the MIA is based on that model.

rcaselli

rcaselli 9分前

Just knowing JCTB1 is here is good enuf for me, okay.
See ya all topside….
$LBRG

Idunno

Have at it Brazen! ;) … .. . :)

CatfishHunter

CatfishHunter 11分前

Every biotech founder believes their design choice was the right one — that’s true of BetaGlue’s surgeon-founder and it was true of Fisher/Korenko too. Design rationale explains intent, not outcome. The question that matters is what the trial data shows for each product, not why either team picked t

asp42001

asp42001 11分前

Digital USIO & AI Payment Potential:

(USIO In-Part):

"Embedded payments are the hidden engine under the hood of the apps and platforms we use every day. When you buy a ticket through a sports app or pay for a round of golf lessons online, embedded payments are doing the

BigBadWolf

BigBadWolf 12分前

$Ownership😘 of @ this point w/ irrefutable DD
🤔https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177573771&txt2find=reactor

mgland

mgland 13分前

https://x.com/thommic/status/2072760144774005081

GTF

Just so you know the clock on the 12 month restricted period for SNTX divvy shares began on June 17th, 2026. It doesn't matter that the deliverance of shares to the gtvh shareholders is taking some time. The clock begins when SNTX creates and issues the shares...meaning the day OTCmarkets shows the

manibiotech

manibiotech 15分前

I like this line in couple of PSM analysis slides:

“ Conclusion: Based on these more precisely matched comparisons,
the survival benefit with DCVax-L was likely underestimated
in the original analysis”

Very encouraging . Now let’s see when MHRA does its jo

ErnieBilco

ErnieBilco 16分前

Good to know because I was thinking about letting it go but now I have a reason to hold

gdog

This is by far the Best piece Gary has written imho

https://garywallach.substack.com/p/from-qualification-to-harvest-could?r=3iu9hl&utm_campaign=post&utm_medium=web&triedRedirect=true

AngeloFoca

AngeloFoca 17分前

I doubt you will agree or bother reading what I have said but at least it wasn’t written by some AI.
I have read it all and you are right... I don't agree with ANY of it.

No, I don't believe they have done EVERYTHING right... But I do believe that had it been any other CEO...

rmoss

Stay away stay very far away........

flipper44

flipper44 19分前

I’m busy today, but these results are in line with what I expected. Excellent, and very helpful for all current and potential stakeholders. Great for patients! For current therapy as well as future improvements with combination therapy. Happy 4th Tomorrow! (Top notch for valuation)

stoxjock

stoxjock 20分前

Ok, This Explains it. I didn't know which Wall St (Or elsewhere in Europe like James St) Scoundrel "Creditors' were "Filing TWICE or even More' to get their Money from multiple Lehman Entities ..Frankly, those SCUM should be prosecuted for Fraud and Thrown in Jail for Good...

Arqiva Financing

Brunello Cucinelli (PK)

Bmo Canadian Equity Fund...

Kadestone Capital

Eden Innovations

AusNet Services

Greenpower Energy

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。